| Splenic Lymphoma studied in …STUDIED_INderived10 of 166show all (up to 200) |
|---|
| → studied in | NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07055477Phase 1 · recruiting A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113500Phase 2 · active not recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07759661not yet recruiting Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05735834Phase 3 · active not recruiting Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05377827Phase 1 · suspended Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638722Phase 2 · not yet recruiting Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Splenic Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07691450Phase 1 · not yet recruiting Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma · condition mapped CURATED_BROADER · 166 trials mapped (20 active) | — | — | Hepatosplenic T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |